Survival Benefits From Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma and Microvascular Invasion After Curative Hepatectomy.

Mu-Gen Dai,Si-Yu Liu,Wen-Feng Lu,Lei Liang,Bin Ye

Clinical Medicine Insights. Oncology（2023）

引用 0|浏览2

暂无评分

摘要

Postoperative adjuvant targeted therapy can improve the long-term prognosis of patients with HCC and MVI. Therefore, in clinical practice, oral lenvatinib should be recommended for patients with HCC and MVI to decrease tumor recurrence and improve long-term survival.

查看译文

关键词

Hepatocellular carcinoma, adjuvant therapy, lenvatinib, recurrence, overall survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要